iCo Therapeutics Inc. | Income Statement
Fiscal year is January-December. All values CAD Thousands.
2013
2014
2015
2016
2017
2018
Cost of Goods Sold (COGS) incl. D&A
87.00
49.60
22.00
27.40
23.50
1.50
Gross Income
87.00
49.60
22.00
27.40
23.50
1.50
SG&A Expense
6,050.20
2,210.30
2,189.80
1,203.70
1,449.90
2,200.20
EBIT
6,137.20
2,259.90
2,211.80
1,231.10
1,473.40
2,201.70
Unusual Expense
523.30
107.00
7.90
470.00
2.80
-
Non Operating Income/Expense
71.40
322.30
368.10
194.60
232.50
498.70
Pretax Income
5,668.20
2,009.10
1,794.90
1,489.90
1,237.30
1,702.60
Consolidated Net Income
5,668.20
2,009.10
1,794.90
1,489.90
1,237.30
1,702.60
Net Income
5,668.20
2,009.10
1,794.90
1,489.90
1,237.30
1,702.60
Net Income After Extraordinaries
5,668.20
2,009.10
1,794.90
1,489.90
1,237.30
1,702.60
Net Income Available to Common
5,668.20
2,009.10
1,794.90
1,489.90
1,237.30
1,702.60
EPS (Basic)
0.09
0.02
0.02
0.02
0.01
0.02
Basic Shares Outstanding
61,484.60
84,457.70
84,457.70
84,457.70
84,457.70
84,457.70
EPS (Diluted)
0.09
0.02
0.02
0.02
0.01
0.02
Diluted Shares Outstanding
61,484.60
84,457.70
84,457.70
84,457.70
84,457.70
84,457.70
EBITDA
6,050.20
2,210.30
2,189.80
1,203.70
1,449.90
2,200.20
Non-Operating Interest Income
17.10
35.70
40.90
16.60
6.40
0.40
About iCo Therapeutics
View Profile
